The new board is comprised of Mark Wilcox, MD, who will serve as chair; Curtis Donskey, MD; Ciarán Kelly, MD; and Tom Louie, MD. Synthetic Biologics plans to initiate phase Ia and Ib clinical trials to evaluate SYN-004 in the second half of 2014.
“SYN-004 has the potential to have a significant impact on mitigating this urgent public health threat, and I look forward to working with the other advisory board members to help the company move this promising program forward as expeditiously and strategically as possible,” said Dr. Wilcox in a news release.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.